Disparities in care among patients with low-grade serous ovarian carcinoma.
Adolescent
Adult
Aged
Aged, 80 and over
Black People
/ statistics & numerical data
Cystadenocarcinoma, Serous
/ economics
Female
Healthcare Disparities
/ economics
Hispanic or Latino
/ statistics & numerical data
Humans
Insurance Coverage
Middle Aged
National Health Programs
Ovarian Neoplasms
/ economics
Survival Rate
United States
/ epidemiology
White People
/ statistics & numerical data
Young Adult
Age
Disparities
Ethnic
Low-grade serous carcinoma
NCDB
Ovarian cancer
Racial
Survival
Journal
Gynecologic oncology
ISSN: 1095-6859
Titre abrégé: Gynecol Oncol
Pays: United States
ID NLM: 0365304
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
16
08
2019
revised:
23
11
2019
accepted:
25
12
2019
pubmed:
6
2
2020
medline:
7
10
2020
entrez:
4
2
2020
Statut:
ppublish
Résumé
Low-grade serous carcinoma (LGSC) is a rare histotype of ovarian cancer with a unique disease course. Little data exist regarding the influence of sociodemographic factors on diagnosis and outcomes in this disease. Our objective was to evaluate the associations between these factors and the clinical characteristics, treatment approaches, and survival in LGSC. The National Cancer Database (NCDB) was queried for data between 2004 and 2015 on patients with LGSC. LGSC was inclusive of invasive, grade 1, serous carcinoma of the ovary, fallopian tube, or peritoneum. Patient demographics, insurance status, disease characteristics, treatment approach, and survival were evaluated. ANOVA, Chi Square, Kaplan-Meier, and Cox regression were used in the analysis. 3221 patients with LGSC were evaluated (89.5% White, 6.2% Black; 7.2% Hispanic, 92.8% non-Hispanic). Compared to Whites, Blacks were diagnosed younger (50.4 vs. 55.9 years, p < 0.01), received less chemotherapy (61.8% vs 67.0%, p = 0.04), and had less CA-125 elevation (OR 4.14 [1.26-13.57], p = 0.02). Compared to non-Hispanics, Hispanics were younger (49.5 vs. 55.8 years, p < 0.01) and received less chemotherapy (55% vs 67%, p < 0.001). In contrast to private insurance, government insurance was associated with a higher 30-day mortality (1.5% vs 0.01%, p < 0.001). Race/ethnicity were not predictive of OS, while older age (HR 1.013 [1.002-1.024], p = 0.03), advanced stage (HR 3.09 [2.15-4.43], p < 0.001), and government insurance (HR 2.33 [1.65-3.30], p < 0.001) were all independently associated with worse OS. Significant differences exist in the clinical characteristics, treatments, and outcomes of LGSC by sociodemographics, with Blacks and Hispanics being diagnosed younger and receiving less chemotherapy. Age, stage, and insurance status were predictive of overall survival.
Identifiants
pubmed: 32008792
pii: S0090-8258(19)31871-2
doi: 10.1016/j.ygyno.2019.12.041
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
46-54Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors of this paper have no conflicts of interest to disclose.